QuickMIC® proves superior speed and performance in multicenter study
The diagnostics company Gradientech announces a new scientific publication of the QuickMIC® system, the today fastest diagnostic system on the market for antibiotic susceptibility testing (AST) of blood cultures from patients with sepsis. The article is published in the top-tier Journal of Clinical Microbiology.
The multicenter study aimed to evaluate the performance of the QuickMIC system regarding speed, precision, accuracy and reproducibility compared to the reference method broth microdilution (BMD). The study contains an extensive collection of clinical samples, including challenging strains totalling 559 different organisms, and was conducted in collaboration with three leading European hospitals.
Clinical study data from the performance evaluation of the QuickMIC system shows that QuickMIC is highly accurate compared to the reference testing method for AST. QuickMIC provides 95.6% agreement with the reference MIC values (Minimum Inhibitory Concentration) and over two times higher precision compared to broth microdilution. The mean analysis time was 3h and 13 min.
According to the authors, “The microfluidics generated linear gradient by the QuickMIC system ensures high repeatability and reproducibility between laboratories, thus allowing a high level of trust in MIC values from single testing compared to BMD”.
“This is a pivotal study for our technology, showing beyond doubt that the QuickMIC system delivers rapid and accurate AST test results, which is important in the management of severe disease such as sepsis. Rapid diagnostic technologies such as QuickMIC are also increasingly a necessity for antimicrobial stewardship and the prevention of antibiotic resistance, and we are excited to provide a new tool in this important struggle,” says Christer Malmberg, Chief Scientist at Gradientech.
The study is published in the Journal of Clinical Microbiology, a top-tier scientific journal published by the American Society for Microbiology. To access the full article, follow the link below:
https://journals.asm.org/doi/10.1128/jcm.00458-24
The QuickMIC system's ultra-rapid and precise AST results enable sepsis patients to receive specific personalised guidance on the right antibiotic in record time. The modular design offers affordable scaling possibilities, making QuickMIC attractive to both small and large hospital laboratories. QuickMIC and its Gram-negative panel are CE marked and commercially available in Europe but not yet available for sale in the United States.
For further information, please contact:
Sara Thorslund, PhD, CEO
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se
Christer Malmberg, PhD, Chief Scientist
Tel: +46 762 01 40 11
christer.malmberg@gradientech.se
About Gradientech
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.
